RxDoctor Payments Data

Angela Bessette, MD

Ophthalmology · Rochester, NYNPI 1912296088

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 27 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by AbbVie at 28.8% of the total. That places this record below the midpoint for ophthalmology clinicians in NY, where the typical reported total is $1,047.

$729in general payments, 2019–2025

Across 27 payments — averaging $27.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$210
  • Genentech USA, Inc.$160
  • ANI Pharmaceuticals, Inc.$139
  • Astellas Pharma US Inc$57
  • Regeneron Healthcare Solutions, Inc.$49
  • Bausch & Lomb Americas Inc.$46
  • plus $69 from 3 others
$17,800in research payments, 2019–2025

Across 1 payment — averaging $17,800 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$18K

What the payments were for

  • Food & beverage$729100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$729 in reported general payments places this provider in the 40th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York →

Medicare billing

Part B allowed, 2024
$1,114,470
Medicare patients
302
Services billed
11,221

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate102$5,135
Bromfenac Sodium17$2,729
Difluprednate11$1,313
Ketorolac Tromethamine44$597
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat38$431
Brimonidine Tartrate42$265
Timolol Maleate35$239
Dorzolamide Hcl13$227
Latanoprost26$150
Prednisone11$74
Tobramycin12$56

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Rochester

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →